Outcomes of Patients Treated in the UK Proton Overseas Programme: Central Nervous System Group
Outcomes of Patients Treated in the UK Proton Overseas Programme: Central Nervous System Group
复制标题
DOI：
10.1016/j.clon.2023.01.024
复制
发表时间：
2023-04-07
影响因子：
3.4
通讯作者：
Smith, E.
中科院分区：
文献类型：
--
作者：
Gaito, S.;Hwang, E. J.;Smith, E.
目的：2008年，联合王国国民保健服务启动了质子海外方案（POP），为选定的肿瘤诊断提供国外质子束治疗（PBT）的机会，同时正在规划两个国家中心。本文报告了治疗中枢神经系统（CNS）、颅底、脊柱和脊柱旁恶性肿瘤的患者组的临床结果。材料和方法：自POP启动以来，国家卫生服务和联合王国转诊中心之间的协议确保了结果数据的收集，包括总体生存、局部肿瘤控制和晚期毒性数据。临床和治疗相关数据从这个国家患者数据库中提取。根据不良事件通用术语标准（CTCAE） v 4.0定义，报告>= 3级晚期毒性，发生于治疗完成后90天。结果：2008年至2020年9月，830名患者在POP内接受了上述恶性肿瘤的治疗。815例患者的总体生存数据和726例患者的局部对照数据。702例患者进行毒性分析，因随访时间短（= 3）而被排除（晚期毒性发生率为11.97%），中位随访时间为1.72年（0.04-8.45）。放疗处方中位剂量为54 GyRBE（34.8-79.2）。结论：本研究结果表明PBT治疗中枢神经系统肿瘤是安全的。PBT治疗在POP内治疗的儿童/青少年和年轻人以及成人中枢神经系统肿瘤的初步临床结果令人鼓舞，这反映了准确的患者选择和治疗质量。晚期效应率与已发表的队列比较有利。该患者队列的临床结果将与自2018年国家PBT服务启动以来在英国接受治疗的患者的临床结果进行比较。(c) 2023皇家放射科医师学院。Elsevier Ltd.出版。版权所有。
Aims: In 2008, the UK National Health Service started the Proton Overseas Programme (POP), to provide access for proton beam therapy (PBT) abroad for selected tumour diagnoses while two national centres were being planned. The clinical outcomes for the patient group treated for central nervous system (CNS), base of skull, spinal and paraspinal malignancies are reported here.Materials and methods: Since the start of the POP, an agreement between the National Health Service and UK referring centres ensured outcomes data collection, including overall survival, local tumour control and late toxicity data. Clinical and treatment-related data were extracted from this national patient database. Grade >= 3 late toxicities were reported following Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 definition, occurring later than 90 days since the completion of treatment.Results: Between 2008 and September 2020, 830 patients were treated within the POP for the above listed malignancies. Overall survival data were available for 815 patients and local control data for 726 patients. Toxicity analysis was carried out on 702 patients, with patients excluded due to short follow-up (= 3 late toxicity incidence was 11.97%, after a median follow-up of 1.72 years (0.04-8.45). The median radiotherapy prescription dose was 54 GyRBE (34.8-79.2).Conclusions: The results of this study indicate the safety of PBT for CNS tumours. Preliminary clinical outcomes following PBT for paediatric/teen and young adult and adult CNS tumours treated within the POP are encouraging, which reflects accurate patient selection and treatment quality. The rate of late effects compares favourably with published cohorts. Clinical outcomes from this patient cohort will be compared with those of UK-treated patients since the start of the national PBT service in 2018. (c) 2023 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.